Views Expressed Disclaimer:
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Highlights

  • Telix reported quarterly EPS of USD -0.01, missing estimates by USD 0.06.
  • Revenue reached USD 413.4M, below consensus expectations of USD 421.5M.
  • FY2026 revenue guidance set at USD 950–970M amid higher R&D spending.

Telix Pharmaceuticals (NASDAQ:TLX) reported quarterly earnings per share of USD -0.01, compared with market expectations of USD 0.05, representing a shortfall of USD 0.06. Quarterly revenue came in at USD 413.4M, below the consensus estimate of USD 421.5M.

The results reflect a gap between reported performance and analyst projections during the quarter, even as the company highlighted full-year progress.

FY2025 Growth and 2026 Outlook
For FY2025, Telix recorded revenue of USD 804M, marking a 56% increase year over year. Precision medicine revenue totaled USD 622M, up 22%. The company ended the year with an approximate cash balance of USD 142M.

Looking ahead, Telix issued FY2026 revenue guidance in the range of USD 950M to USD 970M, indicating expected growth of more than 20%. Management identified its precision-medicine portfolio as a central contributor, supported by commercial products including Gleolan and clinical milestones such as ProstACT part-one safety data and a planned interim readout for part two later in 2026.

Investment Plans and Cost Outlook
The company plans to increase research and development spending to between USD 200M and USD 240M in 2026. It indicated that the majority of earnings will be reinvested into R&D, commercial operations, and infrastructure initiatives.

This reinvestment strategy may weigh on near-term reported profitability through 2026 and 2027 as spending levels rise. Telix has also invested more than USD 500M historically in manufacturing and supply capabilities. The RLS acquisition delivered positive EBITDA during its first 11 months, contributing to internal production capacity.

Regulatory Risks Remain in Focus
Regulatory developments remain a key consideration. Pixclara and Zircaix were not approved in 2025 and require resubmissions and chemistry, manufacturing, and controls remediation. The timing of potential approvals and subsequent commercial launches remains uncertain, adding execution risk to forward plans.

Share performance
Telix Pharmaceuticals shares declined 7.00% to 9.70 AUD on 20 February. The stock is now down 14.61% year to date, reflecting continued selling pressure and cautious investor sentiment in the healthcare sector.

Broker Consensus Indicates Upside with Buy Rating
According to EODHD/Others data dated 23 February 2026, analysts maintain a highly positive outlook on Telix Pharmaceuticals Ltd, with the current consensus recommendation at 1.4 (STRONG BUY). The average target price stands at USD 19.29, implying a significant upside potential of approximately 150.85% from current levels around USD 7.69.

The bullish stance reflects confidence in the company’s radiopharmaceutical pipeline and commercial execution. Overall, broker sentiment suggests strong growth expectations and meaningful re-rating potential ahead.

Company Overview
Telix Pharmaceuticals is a clinical-stage biopharmaceutical company developing and commercializing molecularly targeted radiopharmaceuticals for cancer diagnosis and treatment. Its pipeline includes both imaging and therapeutic candidates across multiple tumor types.

Telix Pharmaceuticals reported a quarterly EPS miss and revenue below expectations, despite delivering 56% annual revenue growth in FY2025. With FY2026 guidance targeting up to USD 970M in revenue and increased R&D spending planned, the company faces a period of elevated investment alongside regulatory uncertainties tied to Pixclara and Zircaix. Market participants are monitoring execution progress, clinical updates, and the impact of higher spending on near-term profitability.

FAQs

Q1. What were Telix Pharmaceuticals’ latest quarterly results?
A:-The company reported EPS of USD -0.01 and revenue of USD 413.4M, both below consensus estimates.

Q2. What is Telix’s revenue guidance for FY2026?
A:-Telix expects FY2026 revenue between USD 950M and USD 970M.

Q3. What regulatory challenges is Telix facing?
A:-Pixclara and Zircaix were not approved in 2025 and require resubmissions and remediation before potential approval.